Screener
Evommune EVMN Q3 2026 earnings
Reported November 12, 2026 · After market close
EPS-$0.85Miss by $0.02
Revenue estimate$428.6K
EPS estimate-$0.83
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
Q3 2026-$0.85Miss by $0.02
Q2 2026-$0.89Miss by $0.23Q1 2026-$0.64Beat by $0.19Q4 2025-$1.43Miss by $0.61Q3 2025-$8.07Miss by $1.99FAQ
- When did Evommune report Q3 2026 earnings?
- Evommune (EVMN) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Evommune's Q3 2026 revenue and EPS?
- Evommune reported eps of $-0.85 for Q3 2026.
- Did Evommune beat estimates in Q3 2026?
- EPS missed the consensus estimate of $-0.83 by $0.02.
- How did Evommune's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 89.5% from $-8.07.
- Where can I find Evommune's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-458329) and the 10-Q periodic report (0001193125-26-458385) directly on SEC EDGAR. The filing index links above go to sec.gov.
